Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Scancell inks collaboration deal with leading US lung cancer foundation

It is teaming up with the Addario Lung Cancer Medical Institute (ALCMI) and the Bonnie J Addario Lung Cancer Foundation.
Scancell inks collaboration deal with leading US lung cancer foundation
Lung cancer remains one of the most difficult cancers to treat and accounts for more than a quarter of all cancer deaths

Scancell Holdings Plc (LON:SCLP) has inked a US collaboration deal with a leading lung cancer foundation that will accelerate the development of a ground-breaking immuno-oncology drug.

It is teaming up with the Addario Lung Cancer Medical Institute (ALCMI) and the Bonnie J Addario Lung Cancer Foundation to take its SCIB2 cancer vaccine in phase I/II clinical trials.

Patients with non-small cell lung cancer (NSCLC) will receive the treatment.

ALCMI will assist Scancell with the design and development of the study, which is set to get underway in 2018 and complete around 18 months later.

 “We have generated preclinical data that suggests that SCIB2 could be the ideal complement to existing and emerging checkpoint inhibitor therapies to treat NSCLC and so provide an effective new potential treatment option for patients with this devastating disease,” said Scancell CEO Richard Goodfellow.

Lung cancer remains one of the most difficult cancers to treat and accounts for more than a quarter of all cancer deaths.

That’s more than breast, prostate and colon cancers combined. Around 228,000 people receive a cancer diagnosis in the US alone and more than 160,000 will not survive.

“This partnership enables us to access an important clinical programme that could also accelerate the development of this ground-breaking immunotherapy technology,” said ALCMI president Steven Young.

SCIB2 was developed using the company’s ImmunoBody cancer vaccine platform.

It is a new breed of immunotherapy treatment that stimulates the body’s own defences to potentially treat and prevent cancer.

The company recently successfully completed a Phase I/II clinical trial with SCIB1 in patients with melanoma.

“Immunotherapy has dramatically improved many patients' outcomes across various cancer types,” said Jacob Sands, assistant professor of medical oncology at the Lahey Hospital & Medical Center, one of the ALCMI member institutions.

“One of the next steps is how we can further enhance the immune response to cancer. Early clinical data on ImmunoBody suggests it is extremely well tolerated and may significantly improve outcomes, which would be ideal.

“I'm excited to work with Scancell and hopeful that we will take another important step in the fight against lung cancer.” 

View full SCLP profile View Profile

Scancell Holdings Plc Timeline

Related Articles

3d rendering of an antibody
July 24 2018
It is teaming up with Bach BioSciences, a company commercialising the research of William Bachovchin, a professor at Tufts University School of Medicine, Boston
September 25 2018
The drug developer had originally to recruit 80 people for the second part of its phase II study of its SNG001 treatment, but it will now assess 120 patients
nizoral shampoo
June 19 2018
The new product will be the company's fourth international star brand

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use